In Victory For Teva, Federal Circuit Sends Accupril Patent Suit Back To New Jersey

Law360, New York (August 11, 2005, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has ruled in favor of Israeli generics maker Teva Pharmaceuticals in a lawsuit brought by Pfizer Inc., asking a New Jersey federal court to review a decision that halted sales of a generic version of the hypertension drug Accupril.

The appeals court upheld a ruling by the U.S. District Court for the District of New Jersey that the disputed patent is not unenforceable by reason of inequitable conduct.

However, the court noted that “there are genuine issues...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.